Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 30694001.
- Also identified by DOI 10.1002/hed.25473 and PMC identifier 6667900.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report the performance of a gene expression profile test to classify the recurrence risk of cutaneous melanoma tumors of the head and neck as low-risk Class 1 or high-risk Class 2. Of note, 157 primary head and neck cutaneous melanoma tumors were identified. Survival analyses were performed using Kaplan-Meier and Cox methods. Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method (P < .0001 for all end points), and both were independent predictors of recurrence in multivariate analysis. Overall, 74% of distant metastases and 88% of melanoma-specific deaths had Class 2 risk. The gene expression profile test identifies cases at increased risk for metastasis and death independent of a clinically or pathologically negative nodal status, suggesting that incorporation of this molecular tool could improve clinical management of patients with head and neck cutaneous melanoma, especially in those with a negative sentinel lymph node biopsy.
Medical subject headings
- Gene Expression Profiling
- Head and Neck Neoplasms
- Lymph Nodes
- Melanoma
- Skin Neoplasms